All In Biotech

Drug Trial Radar · NCT01113229

Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 1,721 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,721

Actual

Start

Mar 2010

Primary completion

Jul 2014

Study completion Dec 2014

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
URC-CIC Paris Descartes Necker Cochin
First posted
Apr 29, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate that the combined used of oxytocin and misoprostol prevent from post partum haemorrhage better than oxytocin alone, following vaginal birth at 36 to 42 weeks.

Conditions

  • Hemorrhage; Complicating Delivery

Interventions

  • MisoprostolDrug

    two misoprostol tablets taken orally (400µg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of post partum hemorrhage > 500mL in 1 hourTime frame: 1 HOUR

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chi Poissy St Germain

    Poissy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.